Vaccination against human papillomavirus after adjuvant therapy of cervical intraepithelial neoplasia

Background. The relevance of the problem is supported by the lack of effective secondary prevention measures against human papillomavirus (HPV)-associated cervical intraepithelial neoplasia (CIN) and cervical cancer. The only currently verified treatment for lower genital neoplasia is destructive therapy, with the recurrence rate of viral infection remaining quite high even after such interventions. The preventive role of HPV vaccine at pre-existing cervical lesions is actively debated worldwide, but the evidence remains scattered and contradictory. The present study surveys the scientific publications available that evaluate the efficacy of human papillomavirus vaccination as a secondary prevention measure against related cervical pathology.
Objectives. An evidence survey on the efficacy of adjuvant vaccination against human papillomavirus in patients undergoing destructive therapy for cervical intraepithelial neoplasia.
Methods. We have conducted a 10 year-depth review of scientific literature on the adjuvant human papillomavirus (HPV) vaccination efficacy for reducing the recurrence risk of precancerous cervical neoplasia. The results are presented in form of the difference of mean or pooled 95% confidence-interval odds ratios (OR; 95% CI). Statistical analyses were conducted with Review Manager v. 5.4 (The Cochrane Collaboration, 2020).
Results. Thirteen Russian- and English-language studies were selected for final analysis. A total of 21,702 cervical dysplasia patients were included: 5,941 (27.4%) received a perioperative HPV vaccine, while 15,761 (72.6%) only had surgical treatment. Recurrences of CIN I (mild cervical intraepithelial neoplasia; OR 0.45, 95% CI 0.27–0.73; p = 0.001) and CIN II (moderate cervical intraepithelial neoplasia; OR 0.33, 95% CI 0.20–0.52; p <0.0001) were lower in the vaccinated vs. unvaccinated cohort.
Conclusion. Adjuvant HPV vaccination associates with a lower risk of recurrence in cervical intraepithelial neoplasia. Further research is necessary to shed more light on the role of human papillomavirus vaccination as a secondary prevention measure against its associated lesions.

1. Harper D.M., DeMars L.R. HPV vaccines — A review of the first decade. Gynecol. Oncol. 2017; 146(1): 196–204. DOI: 10.1016/j.ygyno.2017.04.004

2. Bogani G., Leone Roberti Maggiore U., Signorelli M., Martinelli F., Ditto A., Sabatucci I., Mosca L., Lorusso D., Raspagliesi F. The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. Crit. Rev. Oncol. Hematol. 2018; 122: 92–97. DOI: 10.1016/j.critrevonc.2017.12.017

3. Sankaranarayanan R. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy. Int. J. Gynaecol. Obstet. 2015; 131, Suppl 1: S33–35. DOI: 10.1016/j.ijgo.2015.02.014

4. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018; 68(1): 7–30. DOI: 10.3322/caac.21442

5. Pils S., Joura E.A. From the monovalent to the nine-valent HPV vaccine. Clin. Microbiol. Infect. 2015; 21(9): 827–833. DOI: 10.1016/j.cmi.2015.05.001

6. Radley D., Saah A., Stanley M. Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Hum. Vaccin. Immunother. 2016; 12(3): 768–772. DOI: 10.1080/21645515.2015.1088616

7. Meites E., Szilagyi P.G., Chesson H.W., Unger E.R., Romero J.R., Markowitz L.E. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly. Rep. 2019; 68(32): 698– 702. DOI: 10.15585/mmwr.mm6832a3

8. Roden R.B.S., Stern P.L. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat. Rev. Cancer. 2018; 18(4): 240–254. DOI: 10.1038/nrc.2018.13

9. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R.; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2): 1–24.

10. Ranjeva S.L., Baskerville E.B., Dukic V., Villa L.L., Lazcano-Ponce E., Giuliano A.R., Dwyer G., Cobey S. Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity. Proc. Natl. Acad. Sci. USA. 2017; 114(51): 13573–13578. DOI: 10.1073/pnas.1714712114

11. Mariz F.C., Bender N., Anantharaman D., Basu P., Bhatla N., Pillai M.R., Prabhu P.R., Sankaranarayanan R., Eriksson T., Pawlita M., Prager K., Sehr P., Waterboer T., Müller M., Lehtinen M. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020; 5(1): 14. DOI: 10.1038/s41541-020-0165-x

12. Athanasiou A., Bowden S., Paraskevaidi M., Fotopoulou C., Martin-Hirsch P., Paraskevaidis E., Kyrgiou M. HPV vaccination and cancer prevention. Best. Pract. Res. Clin. Obstet. Gynaecol. 2020; 65: 109–124. DOI: 10.1016/j.bpobgyn.2020.02.009

13. Ault K.A. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol. Oncol. 2007; 107(2 Suppl 1): S31–33. DOI: 10.1016/j.ygyno.2007.08.059

14. De Vincenzo R., Ricci C., Conte C., Scambia G. HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol. Oncol. 2013; 130(3): 642–651. DOI: 10.1016/j.ygyno.2013.05.033

15. Saftlas A.F., Spracklen C.N., Ryckman K.K., Stockdale C.K., Penrose K., Ault K., Rubenstein L.M., Pinto L.A. Influence of a loop electrosurgical excision procedure (LEEP) on levels of cytokines in cervical secretions. J. Reprod. Immunol. 2015; 109: 74–83. DOI: 10.1016/j.jri.2015.01.002

16. Frazer I.H. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009; 384(2): 410–414. DOI: 10.1016/j.virol.2008.10.004

17. Zurek Munk-Madsen M., Toft L., Kube T., Richter R., Ostergaard L., Søgaard O.S., Tolstrup M., Kaufmann A.M. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. Hum. Vaccin. Immunother. 2018; 14(4): 909–916. DOI: 10.1080/21645515.2017.1407896

18. Ma Y., Madupu R., Karaoz U., Nossa C.W., Yang L., Yooseph S., Yachimski P.S., Brodie E.L., Nelson K.E., Pei Z. Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets. J. Virol. 2014; 88(9): 4786–4797. DOI: 10.1128/JVI.00093-14

19. Antonsson A., Forslund O., Ekberg H., Sterner G., Hansson B.G. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J. Virol. 2000; 74(24): 11636–11641. DOI: 10.1128/jvi.74.24.11636-11641.2000

20. Knobloch K., Yoon U., Vogt P.M. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J. Craniomaxillofac. Surg. 2011; 39(2): 91–92. DOI: 10.1016/j.jcms.2010.11.001

21. Cumpston M.S., McKenzie J.E., Welch V.A., Brennan S.E. Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition. J. Public. Health. (Oxf). 2022: fdac036. DOI: 10.1093/pubmed/fdac036

22. Kontopantelis E., Springate D.A., Reeves D. A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses. PLoS One. 2013; 8(7): e69930. DOI: 10.1371/journal.pone.0069930

23. Joura E.A., Garland S.M., Paavonen J., Ferris D.G., Perez G., Ault K.A., Huh W.K., Sings H.L., James M.K., Haupt R.M.; FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012; 344: e1401. DOI: 10.1136/bmj.e1401

24. Kang W.D., Choi H.S., Kim S.M. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol. Oncol. 2013; 130(2): 264– 268. DOI: 10.1016/j.ygyno.2013.04.050

25. Garland S.M., Paavonen J., Jaisamrarn U., Naud P., Salmerón J., Chow S.N., Apter D., Castellsagué X., Teixeira J.C., Skinner S.R., Hedrick J., Limson G., Schwarz T.F., Poppe W.A., Bosch F.X., de Carvalho N.S., Germar M.J., Peters K., Del Rosario-Raymundo M.R., Catteau G., Descamps D., Struyf F., Lehtinen M., Dubin G.; HPV PATRICIA Study Group. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Posthoc analysis from a randomized controlled trial. Int. J. Cancer. 2016; 139(12): 2812–2826. DOI: 10.1002/ijc.30391

26. Hildesheim A., Gonzalez P., Kreimer A.R., Wacholder S., Schussler J., Rodriguez A.C., Porras C., Schiffman M., Sidawy M., Schiller J.T., Lowy D.R., Herrero R.; Costa Rica HPV Vaccine Trial (CVT) Group. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am. J. Obstet. Gynecol. 2016; 215(2): 212.e1–212.e15. DOI: 10.1016/j.ajog.2016.02.021

27. Ghelardi A., Parazzini F., Martella F., Pieralli A., Bay P., Tonetti A., Svelato A., Bertacca G., Lombardi S., Joura E.A. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol. Oncol. 2018; 151(2): 229–234. DOI: 10.1016/j.ygyno.2018.08.033

28. Pieralli A., Bianchi C., Auzzi N., Fallani M.G., Bussani C., Fambrini M., Cariti G., Scarselli G., Petraglia F., Ghelardi A. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease. Arch. Gynecol. Obstet. 2018; 298(6): 1205–1210. DOI: 10.1007/s00404-018-4926-y

29. Ortega-Quiñonero P., Remezal-Solano M., Carazo-Díaz M.C., Prieto-Merino D., Urbano-Reyes M., de Guadiana-Romualdo L.G., Martínez-Cendán J.P. Impact of the human papillomavirus vaccination on patients who underwent conization for high-grade cervical intraepithelial neoplasia. Eur. J. Gynaecol. Oncol. 2019; 40: 402–407. DOI: 10.12892/ejgo4628.2019

30. Sand F.L., Kjaer S.K., Frederiksen K., Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int. J. Cancer. 2020; 147(3): 641–647. DOI: 10.1002/ijc.32752

31. Petrillo M., Dessole M., Tinacci E., Saderi L., Muresu N., Capobianco G., Cossu A., Dessole S., Sotgiu G., Piana A. Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution’s Experience. Vaccines (Basel). 2020; 8(1): 45. DOI: 10.3390/vaccines8010045

32. Del Pino M., Martí C., Torras I., Henere C., Munmany M., Marimon L., Saco A., Torné A., Ordi J. HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions. Vaccines (Basel). 2020; 8(2): 245. DOI: 10.3390/vaccines8020245

33. Bogani G., Raspagliesi F., Sopracordevole F., Ciavattini A., Ghelardi A., Simoncini T., Petrillo M., Plotti F., Lopez S., Casarin J., Serati M., Pinelli C., Valenti G., Bergamini A., Gardella B., Dell’Acqua A., Monti E., Vercellini P., D’ippolito G., Aguzzoli L., Mandato V.D., Carunchio P., Carlifante G., Gianella L., Scaffa C., Falcone F., Ferla S., Borghi C., Ditto A., Malzoni M., Giannini A., Salerno M.G., Liberale V., Contino B., Donfrancesco C., Desiato M., Perrone A.M., Dondi G., De Iaco P., Leone Roberti Maggiore U., Signorelli M., Chiappa V., Ferrero S., Sarpietro G., Matarazzo M.G., Cianci A., Bocio S., Ruisi S., Guerrisi R., Brusadelli C., Mosca L., Tinelli R., De Vincenzo R., Zannoni G.F., Ferrandina G, Dessole S, Angioli R, Greggi S, Spinillo A, Ghezzi F, Colacurci N, Fischetti M., Carlea A., Zullo F., Muzii L., Scambia G., Benedetti Panici P., Di Donato V. Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison. Vaccines (Basel). 2020; 8(4): 717. DOI: 10.3390/vaccines8040717

34. Karimi-Zarchi M., Allahqoli L., Nehmati A., Kashi A.M., Taghipour-Zahir S., Alkatout I. Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial. BMC Public. Health. 2020; 20(1): 274. DOI: 10.1186/s12889-020-8371-z

35. Zarochentseva N.V., Dzhidzhikhiya L.K., Nabieva V.N. Effectiveness of HPV vaccination in preventing recurrent cervical intraepithelial neoplasia after excisional treatment. Gynecology, Obstetrics and Perinatology. 2021; 20(4): 38–44 (In Russ., English abstract). DOI: 10.20953/1726-1678-2021-4-38-44

36. Bogani G., Raspagliesi F., di Donato V., Brusadelli C., Guerrisi R,. Pinelli C., Casarin J., Ghezzi F., Del Fabro A., Ditto A., Simoncini T., Ciavattini A., Sopracordevole F. Spotlight on the role of human papillomavirus vaccines. Gynecol. Oncol. 2021; 160(1): 346–350. DOI: 10.1016/j.ygyno.2020.08.034

37. Bogani G., Sopracordevole F., Di Donato V., Ciavattini A., Ghelardi A., Lopez S., Simoncini T., Plotti F., Casarin J., Serati M., Pinelli C., Valenti G., Bergamini A., Gardella B., Dell’acqua A., Monti E., Vercellini P., Fischetti M., D’ippolito G., Aguzzoli L., Mandato V.D., Carunchio P., Carlinfante G., Giannella L., Scaffa C., Falcone F., Borghi C., Ditto A., Malzoni M., Giannini A., Salerno M.G., Liberale V., Contino B., Donfrancesco C., Desiato M., Perrone A.M., Dondi G., De Iaco P., Chiappa V., Ferrero S., Sarpietro G., Matarazzo M.G., Cianci A., Bosio S., Ruisi S., Guerrisi R., Brusadelli C., Mosca L., Lagana’ A.S., Tinelli R., Signorelli M., De Vincenzo R., Zannoni G.F., Ferrandina G., Lovati S., Petrillo M., Dessole S., Carlea A., Zullo F., Angioli R., Greggi S., Spinillo A., Ghezzi F., Colacurci N., Muzii L., Benedetti Panici P., Scambia G., Raspagliesi F. High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes. Gynecol. Oncol. 2021; 161(1): 173–178. DOI: 10.1016/j.ygyno.2021.01.020

38. Di Donato V., Caruso G., Petrillo M., Kontopantelis E., Palaia I., Perniola G., Plotti F., Angioli R., Muzii L., Benedetti Panici P., Bogani G. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. Vaccines (Basel). 2021; 9(5): 410. DOI: 10.3390/vaccines9050410

39. Di Donato V., Caruso G., Bogani G., Cavallari E.N., Palaia G., Perniola G., Ralli M., Sorrenti S., Romeo U., Pernazza A., Pierangeli A., Clementi I., Mingoli A., Cassoni A., Tanzi F., Cuccu I., Recine N., Mancino P., de Vincentiis M., Valentini V., d’Ettorre G., Della Rocca C., Mastroianni C.M., Antonelli G., Polimeni A., Muzii L., Palaia I. HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis. Vaccines (Basel). 2022; 10(2): 239. DOI: 10.3390/vaccines10020239

40. Zarochentseva N.V., Trushina O.I., Novikova E.G., Baranov I.I., Lopukhov P.D., Rovinskaya O.V. Vaccination against HPV: Theoretical Aspects and Practical Results of Cervical Cancer Prevention. Epidemiology and Vaccinal Prevention. 2019; 18(6): 98–108 (In Russ., English abstract). DOI: 10.31631/2073-3046-2019-18-6-98-108

41. Tumban E.A Current Update on Human Papillomavirus-Associated Head and Neck Cancers. Viruses. 2019; 11(10): 922. DOI: 10.3390/v11100922

42. Marur S., D’Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet. Oncol. 2010; 11(8): 781– 789. DOI: 10.1016/S1470-2045(10)70017-6

43. Davydov A.I., Shakhlamova М.N., Lebedev V.А. Risks for recurrences of papillomavirus infection and methods of their prevention. Gynecology, Obstetrics and Perinatology. 2020; 19(3): 101–106 (In Russ., English abstract). DOI: 10.20953/1726-1678-2020-3-101-106

44. Schiller J.T., Lowy D.R.. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 2012; 10(10): 681– 692. DOI: 10.1038/nrmicro2872

45. Dubrovina S.O., Ardintseva O.A., Varicheva M.V., Gimbut V.S. Opportunities for effective cervical cancer prevention. Obstetrics and Gynecology. 2019; 4: 102– 106 (In Russian, English abstract). DOI: 10.18565/aig.2019.4.102-106

46. Olsson S.E., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., Brown D.R., Koutsky L.A., Tay E.H., García P., Ault K.A., Garland S.M., Leodolter S., Tang G.W., Ferris D.G., Paavonen J., Lehtinen M., Steben M., Bosch F.X., Dillner J., Joura E.A., Majewski S., Muñoz N., Myers E.R., Villa L.L., Taddeo F.J., Roberts C., Tadesse A., Bryan J., Maansson R., Vuocolo S., Hesley T.M., Saah A., Barr E., Haupt R.M. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccin. 2009; 5(10): 696–704. DOI: 10.4161/hv.5.10.9515

47. Szarewski A., Poppe W.A., Skinner S.R., Wheeler C.M., Paavonen J., Naud P., Salmeron J., Chow S.N., Apter D., Kitchener H., Castellsagué X., Teixeira J.C., Hedrick J., Jaisamrarn U., Limson G., Garland S., Romanowski B., Aoki F.Y., Schwarz T.F., Bosch F.X., Harper D.M., Hardt K., Zahaf T., Descamps D., Struyf F., Lehtinen M., Dubin G.; HPV PATRICIA Study Group. Efficacy of the human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine in women aged 15- 25 years with and without serological evidence of previous exposure to HPV-16/18. Int. J. Cancer. 2012; 131(1): 106–116. DOI: 10.1002/ijc.26362

48. Cohen P.A., Anderson L., Eva L., Scurry J. Clinical and molecular classification of vulvar squamous pre-cancers. Int. J. Gynecol. Cancer. 2019; 29(4): 821–828. DOI: 10.1136/ijgc-2018-000135

49. Velentzis L.S., Brotherton J.M.L., Canfell K. Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. Climacteric. 2019; 22(6): 596–602. DOI: 10.1080/13697137.2019.1600500

50. Zhao S., Hu S., Xu X., Zhang X., Pan Q., Chen F., Zhao F. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial. BMC Infect. Dis. 2020; 20(1): 846. DOI: 10.1186/s12879-020-05560-z

51. Dion G.R., Teng S., Boyd L.R., Northam A., Mason-Apps C., Vieira D., Amin M.R., Branski R.C. Adjuvant Human Papillomavirus Vaccination for Secondary Prevention: A Systematic Review. JAMA Otolaryngol. Head. Neck. Surg. 2017; 143(6): 614–622. DOI: 10.1001/jamaoto.2016.4736

52. de Martel C., Plummer M., Vignat J., Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017; 141(4): 664–670. DOI: 10.1002/ijc.30716

53. de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet. Glob. Health. 2020; 8(2): e180–e190. DOI: 10.1016/S2214-109X(19)30488-7

54. Arbyn M., Redman C.W.E., Verdoodt F., Kyrgiou M., Tzafetas M., Ghaem-Maghami S., Petry K.U., Leeson S., Bergeron C., Nieminen P., Gondry J., Reich O., Moss E.L. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet. Oncol. 2017; 18(12): 1665–1679. DOI: 10.1016/S1470-2045(17)30700-3

55. Chesson H.W., Ekwueme D.U., Saraiya M., Watson M., Lowy D.R., Markowitz L.E. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012; 30(42): 6016–6019. DOI: 10.1016/j.vaccine.2012.07.056